Abbott Laboratories (ABT)
Market Cap | 196.91B |
Revenue (ttm) | 40.11B |
Net Income (ttm) | 5.72B |
Shares Out | 1.74B |
EPS (ttm) | 3.26 |
PE Ratio | 34.76 |
Forward PE | 24.32 |
Dividend | $2.20 (1.93%) |
Ex-Dividend Date | Apr 12, 2024 |
Volume | 2,185,824 |
Open | 113.28 |
Previous Close | 113.48 |
Day's Range | 112.93 - 113.94 |
52-Week Range | 89.67 - 121.64 |
Beta | 0.74 |
Analysts | Buy |
Price Target | 125.27 (+10.0%) |
Earnings Date | Apr 17, 2024 |
About ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism,... [Read more]
Financial Performance
In 2023, ABT's revenue was $40.11 billion, a decrease of -8.12% compared to the previous year's $43.65 billion. Earnings were $5.72 billion, a decrease of -17.45%.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for ABT stock is "Buy." The 12-month stock price forecast is $125.27, which is an increase of 10.00% from the latest price.
News
Abbott Hosts Conference Call for First-Quarter Earnings
ABBOTT PARK, Ill., March 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens.
Real-World Data Show Abbott's FreeStyle Libre® Systems and GLP-1 Medicines Work Better Together for People with Type 2 Diabetes
Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results wer...
What's Next For Abbott Stock After A 6% Rise This Year?
Abbott (NYSE: ABT) reported its Q4 results last month, with revenues above and earnings aligning with the street estimates. The company reported revenue of $10.24 billion and earnings of $1.19 on a pe...
Daily Dividend Report: Humana, Fedex, Honeywell, Coca-Cola, Abbott
Humana announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on April 26, 2024 to stockholders of record as of the close of business on M...
Abbott Declares 401st Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Feb. 16, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.
Abbott's heart valve repair device gets FDA advisers' backing
Advisers to the U.S. Food and Drug Administration on Tuesday backed an approval for Abbott Laboratories' heart valve repair device that is designed for patients who are at risk of complications or dea...
Abbott Laboratories says FDA independent panel votes to approve heart device
Abbott Laboratories ABT, -1.06% said that a Food and Drug Administration panel voted in favor of the safety profile of its heart device TriClip.
FDA Advisory Committee Votes in Favor of Abbott's First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve
Panel of independent experts reviewed data from the TRILUMINATE™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip system An investigational device in the U...
US FDA staff raises no new concerns about Abbott's heart device
The U.S. Food and Drug Administration (FDA) staff reviewers did not raise any new concerns on Friday over the safety and effectiveness of Abbott's heart valve repair device designed for patients who a...
Abbott Labs must face lawsuit over PediaSure height claims
A judge has rejected Abbott Laboratories' effort to dismiss a New York City grandmother's lawsuit claiming it misled consumers into believing its PediaSure Grow & Gain nutrition drinks were "clinicall...
New Study Shows Mixed Reality Technology for Blood Donation from Abbott and Blood Centers of America Helps Ease Stress, Encourages People to Donate Again
Mixed reality experience allows blood donors to visit a digital world while remaining fully aware of their surroundings for a safe, relaxing donation 68.4% of pilot study participants who reported pre...
Drugmaker Abbott India's Q3 profit rises on strong demand
Pharmaceutical firm Abbott India reported a 26% rise in third-quarter profit on Thursday, as higher sales outpaced the impact of a pricing cap on certain medicines.
Abbott launches protein shake brand to help people on weight-loss drug
Abbott Laboratories said on Wednesday it has launched a new protein shake that would help adults looking to lose weight and maintain their muscle mass.
Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey
The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of fast- and slow-digesting protein designed to feed m...
Jim Cramer just bought Abbott stock: should you too?
A near 2.0% post-earnings decline in Abbott Laboratories (NYSE: ABT) warrants an investment in the health care giant, says Jim Cramer. Cramer's bullish view on Abbott stock His Charitable Trust bought...
Up Just 6% In 2023 Is Medtronic Stock A Better Pick Over Abbott?
Given its better prospects, we believe Medtronic stock (NYSE: MDT) is a better pick than its peer, Abbott stock (NYSE: ABT). Abbott trades at a higher valuation multiple of 4.9x revenues vs.
Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+
Liberta RC™ deep brain stimulation (DBS) system, recently approved by the U.S. FDA, features NeuroSphere™ Virtual Clinic, which allows for remote programming of the system System offers the longest ti...
Once Slowed By Shutdown, Abbott Labs Says Baby Formula Franchise Back Leading U.S. Market
Less than two years after a headline-grabbing shutdown of a baby formula plant in Michigan that fueled a national crisis, Abbott Laboratories has “reclaimed its previous market-leading position.”
Abbott reports solid results for its fiscal Q4
Abbott Laboratories (NYSE: ABT) is trading down in premarket on Wednesday even though it reported solid results for its fiscal fourth quarter. Why is Abbott stock down on Wednesday?
Abbott Laboratories Stock Is Down. Earnings, Sales Aren't the Problem.
Abbott, a maker of healthcare products, posted fourth-quarter earnings in line with expectations, and beat sales estimates.
Abbott Labs' fourth-quarter sales top estimates amid strong medical-device demand
Abbott Laboratories' stock ABT, -0.17% fell 2% premarket on Wednesday after the healthcare-products company reported fourth-quarter sales that topped expectations amid strength in its medical-device a...
Abbott's strong medical device sales helps meet quarterly profit expectations
Abbott Laboratories on Wednesday reported a fourth-quarter profit that met Wall Street estimates as strong demand for medical devices offset lower-than-expected sales in its pharmaceuticals unit.
Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook
Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the underlying base business increased 11.0 percent Full-year 2023 reported sales decreased 8.1 percent due to anticipated...
Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
Abbott's Volt™ Pulsed Field Ablation System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillation Pulsed field ablation – or PFA – uses hig...
Final Trades: Uber, URNM, Abbott Labs and Vertex Pharma
Brenda Vingiello, Sand Hill Global Advisors CIO, Bryn Talkington, Requisite Capital Management managing partner, Jim Lebenthal, Cerity Partners chief equity strategist, and Josh Brown, Ritholtz Wealth...